Nuvectis Pharma, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDNuvectis Pharma, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 98), indicating clear outperformance against the broad market. Earnings growth of 4% provides fundamental context to the price action. However, with RSI at 91, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $14.51 | +96.64% | ABOVE |
| 50 SMA | $11.73 | +143.26% | ABOVE |
| 100 SMA | $10.12 | +181.96% | ABOVE |
| 150 SMA | $9.30 | +206.76% | ABOVE |
| 200 SMA | $8.51 | +235.30% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is NVCT in an uptrend right now?
NVCT has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, NVCT is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is NVCT overbought or oversold?
NVCT's RSI (14) is 91. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is NVCT outperforming the market?
NVCT has a Relative Strength (RS) Rating of 98 out of 99. Yes, NVCT is a market leader, outperforming 98% of all stocks over the past 12 months.
Where is NVCT in its 52-week range?
NVCT is trading at $28.53, which is 97% of its 52-week high ($29.27) and 97% above its 52-week low ($5.55).
How volatile is NVCT?
NVCT has a Beta of 1.40 and 52-week volatility of 74%. It's more volatile than the S&P 500 - expect bigger swings.